Valuation: Astellas Pharma Inc.

Market Cap 4,466B 28.25B 25.18B 23.31B 21.09B 39.74B 2,666B 40.21B 279B 110B 1,401B 106B 104B P/E 2027 *
11.4x
P/E 2028 * 12.3x
Enterprise Value 4,406B 27.88B 24.84B 23B 20.81B 39.21B 2,631B 39.68B 276B 108B 1,383B 105B 102B EV / Sales 2027 *
1.86x
EV / Sales 2028 * 1.8x
Free-Float
98.92%
Yield 2027 *
3.22%
Yield 2028 * 3.34%
1 day+2.30%
1 week+8.26%
Current month+7.33%
1 month+4.49%
3 months+15.78%
6 months-3.09%
Current year+18.99%
1 week 2,284
Extreme 2284
2,490.5
1 month 2,216
Extreme 2216
2,490.5
Current year 2,041
Extreme 2041
2,717
1 year 1,557.5
Extreme 1557.5
2,717
3 years 1,243.5
Extreme 1243.5
2,717
5 years 1,243.5
Extreme 1243.5
2,717
10 years 1,243.5
Extreme 1243.5
2,717
Manager TitleAgeSince
Chief Executive Officer 64 09/02/2023
Director of Finance/CFO 55 31/10/2023
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 09/02/2023
Director/Board Member 64 31/05/2019
Director/Board Member 59 31/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
+2.30%+8.26%+53.12%+32.33% 27.6B
-0.81%+5.42%+59.37%+120.98% 1,144B
-1.11%+1.03%+33.69%+69.45% 625B
-1.96%-0.01%+22.50%+95.85% 511B
+0.54%+5.69%+39.60%+65.02% 377B
+0.51%+1.10%+70.04%+44.16% 366B
+0.30%+3.44%+21.35%+50.15% 291B
-0.03%+2.55%+1.12%+24.89% 262B
-0.28%+2.74%+45.38%+60.33% 237B
-1.84%-0.19%+23.51%+97.59% 194B
Average -0.22%+6.26%+36.97%+66.08% 403.55B
Weighted average by Cap. -0.62%+6.90%+40.73%+80.97%

Financials

2027 *2028 *
Net sales 2,371B 15B 13.37B 12.38B 11.2B 21.1B 1,416B 21.35B 148B 58.23B 744B 56.28B 55.11B 2,209B 13.98B 12.46B 11.53B 10.44B 19.66B 1,319B 19.9B 138B 54.26B 693B 52.44B 51.35B
Net income 377B 2.38B 2.12B 1.97B 1.78B 3.35B 225B 3.39B 23.59B 9.26B 118B 8.95B 8.76B 345B 2.18B 1.95B 1.8B 1.63B 3.07B 206B 3.11B 21.59B 8.47B 108B 8.19B 8.02B
Net Debt -59.3B -375M -334M -310M -280M -528M -35.4B -534M -3.71B -1.46B -18.61B -1.41B -1.38B -481B -3.04B -2.71B -2.51B -2.27B -4.28B -287B -4.33B -30.08B -11.8B -151B -11.41B -11.17B
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
21/10/26 JP¥2,490.50 +2.30% 5,733,200
20/10/26 JP¥2,434.50 +0.39% 4,807,800
19/10/26 JP¥2,425.00 +0.27% 4,724,000
16/10/26 JP¥2,418.50 +2.63% 6,241,200
15/10/26 JP¥2,356.50 +4.15% 9,143,400
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,490.50JPY
Average target price
2,536.43JPY
Spread / Average Target
+1.84%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.
  1. Stock Market
  2. Stocks
  3. 4503 Stock